ArticleCase reports in transplantation2026
Rapid Onset Fibrosing Cholestatic Hepatitis C Following Transplant of a Hepatitis C Infected Graft Into a Naïve Recipient.
Article in Case reports in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid Onset Fibrosing Cholestatic Hepatitis C Following Transplant of a Hepatitis C Infected Graft Into a Naïve Recipient.Case reports in transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosing cholestatic hepatitis (FCH) is a devastating complication that can occur when hepatitis C virus (HCV) recurs following liver transplantation. When it occurs, FCH typically develops between 1 and 6 months following transplant and is associated with markedly elevated HCV levels. With the advent of direct-acting antiviral therapy, FCH C is now a rare occurrence. Here, we describe a rare case of early-onset FCH that occurred when an HCV nucleic acid test (NAT) positive liver graft was transplanted into a hepatitis C naïve recipient. This case highlights the importance of initiation of antiviral therapy as soon as possible following transplantation of an HCV NAT-positive liver graft as recommended by current guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.